Analyse aandeel Johnson & Johnson

Johnson & Johnson ziet relatief maar enkele belangrijke patenten aflopen in de komende vijf jaar. (Engelstalig rapport)

Damien Conover, CFA 02 oktober, 2014 | 11:54

INVESTMENT THESIS

Johnson & Johnson stands alone as a leader across the major health-care industries. The company maintains a diverse revenue base, a robust research pipeline, and exceptional cash flow generation that together create a wide economic moat.

Johnson & Johnson holds a leadership role in diverse health-care segments, including medical devices, over-the-counter products, and several pharmaceutical markets. Contributing just over a third of total revenue, the pharmaceutical division boasts several industry-leading drugs, including immunology drug Remicade and psoriasis drug Stelara. The medical device and diagnostics group brings in more than 40% of sales, with the company holding controlling positions in many areas, including orthopedics and Ethicon Endo-Surgery's surgical devices. The recent acquisition of Synthes positions the company as a leader in the fast-growing trauma segment. The consumer division largely rounds out the remaining business lines. The 2007 acquisition of Pfizer's consumer business solidified Johnson & Johnson's position in this market.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

Om dit artikel te kunnen lezen, kunt u zich inschrijven als Morningstar Basic Member

Registreer gratis

Effecten genoemd in dit artikel

Naam effectPrijsChange (%)Morningstar Rating
Johnson & Johnson148,25 USD0,72
Novartis AG ADR86,46 USD-0,25
Pfizer Inc36,16 USD1,97
Roche Holding AG336,80 CHF0,36
UCB SA89,30 EUR0,68

Over de auteur

Damien Conover, CFA  Damien Conover, CFA, is an associate director for Morningstar.

Bevestiging bezoeker


Onze website maakt gebruik van cookies en andere technologieën om een op u afgestemde ervaring te kunnen leveren, en te begrijpen hoe u en andere bezoekers onze website gebruiken. Zie 'cookie opties' voor verdere details.

  • Andere Morningstar websites
© Copyright 2018 Morningstar, Inc. Alle rechten voorbehouden.      Gebruiksvoorwaardenen      Privacybeleid.    Cookie toestemming
© Copyright 2020 Morningstar, Inc. Alle rechten voorbehouden.

Voorwaarden        Privacybeleid        Cookies